Blair William & Co. IL decreased its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 62.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,767 shares of the financial services provider’s stock after selling 40,132 shares during the period. Blair William & Co. IL’s holdings in iShares Biotechnology ETF were worth $3,142,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. HHM Wealth Advisors LLC raised its stake in shares of iShares Biotechnology ETF by 200.0% during the fourth quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. VSM Wealth Advisory LLC acquired a new stake in shares of iShares Biotechnology ETF in the 4th quarter worth approximately $30,000. Bradley & Co. Private Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF in the fourth quarter valued at approximately $32,000. Newbridge Financial Services Group Inc. bought a new stake in iShares Biotechnology ETF during the fourth quarter worth approximately $33,000. Finally, Hager Investment Management Services LLC bought a new stake in iShares Biotechnology ETF during the fourth quarter worth approximately $34,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance
Shares of NASDAQ IBB opened at $127.90 on Tuesday. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57. The firm has a market cap of $6.04 billion, a P/E ratio of 27.83 and a beta of 0.84. The stock has a fifty day moving average price of $136.07 and a two-hundred day moving average price of $138.74.
iShares Biotechnology ETF Increases Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.